Research Article
Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema
Table 2
Clinical parameters according to different kidney function.
| | eGFR (ml/min/1.73 m2) | <30 | 30–60 | ≥60 | value |
| | Number (eyes) | 15 | 31 | 51 | | | Age (years, mean ± SD) | 61.0 ± 10.1 | 59.6 ± 8.4 | 61.2 ± 9.6 | 0.75 | | HbA1c (%, mean ± SD) | 7.2 ± 2.2 | 7.1 ± 1.1 | 7.2 ± 1.0 | 0.90 | | PDR (eyes) | 11 (73.3%) | 27 (86.2%) | 38 (75.5%) | 0.55 | | Subretinal fluid (eyes) | | Baseline SRF () | 8 (53.3%) | 17 (54.8%) | 10 (19.6%) | 0.001 | | SRF at 3 months () | 1 (6.7%) | 4 (12.9%) | 0 (0%) | 0.04 | | Central macular thickness (μm) | | Baseline CMT | 392 ± 106 | 456 ± 124 | 406 ± 81 | 0.051 | | CMT at 3 months | 267 ± 72 | 296 ± 84 | 311 ± 78 | 0.17 |
|
|
CMT: central macular thickness; PDR: proliferative diabetic retinopathy; SRF: subretinal fluid.
|
